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1. Introduction 
Prostate cancer (PCA) is the most commonly diagnosed cancer affecting men in many 
countries and it has been estimated that there would be 33, 000 deaths due to PCA in the 
United States in 2011 alone [1]. The standard chemotherapy for metastatic castration-
resistant prostate cancer (CRPC) is the taxane anticancer drug docetaxel in combination with 
the steroid prednisone. In the past two years, autologous immunotherapy sipuleucel-T 
(Provenge), the new taxane drug cabazitaxel (Jevtana) and a P450 C17 inhibitor drug 
abiraterone acetate (Zytiga) were also approved by the US FDA (Food and Drug 
Administration) [2]. Unfortunately, those drugs can only offer limited survival benefit but 
have significant side effects that negatively affect the quality of life of the patients.  
In contrast to chemotherapy, cancer chemoprevention uses naturally occurring or synthetic 
chemicals to block, delay or reverse carcinogenesis, progression and metastasis and is 
increasingly being recognized as essential for winning the war on PCA. Animal models are 
essential for development of effective chemoprevention. Currently, the mouse models used 
for PCA research include human xenograft models in immunocompromised mice, mouse 
prostate reconstitution models, transgenic models and single stem cell-based prostate 
regeneration (see a comprehensive review by Jeet et al. [3]). Considering the facts that PCA 
is a complex disease of uncertain etiology and multifocal phenotypic heterogeneity, a 
desirable model should recapitulate some critical features of human PCA: initiation of PCA 
with PIN (prostatic intraepithelial neoplasia), followed by progression to invasive 
adenocarcinoma, and subsequent metastasis with defined kinetics. Although no single 
model is perfect, transgenic models are widely used to delineate the mechanisms of prostate 
carcinogenesis and evaluate the chemopreventive efficacy of candidate agents because the 
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lesions/cancers develop ‘‘naturally’’ in situ in the genetically engineered hosts and can be 
followed over a long time course [4]. 
2. TRAMP model represents at least two lineages of prostate 
carcinogenesis 
The transgenic adenocarcinoma of mouse prostate (TRAMP) model was originally 
developed by Dr. Greenberg in 1995 [5]. It belongs to the first generation of models based on 
SV40 viral oncogenes [3]. In this TRAMP model, the rat probasin promoter (-426 to 28 bp) 
drives the expression of SV40 large T-antigen (T-Ag) and small t-antigen in the prostate. T-
Ag abrogates P53 and Rb tumor suppressor proteins by direct binding. Simultaneously, 
small t-antigen interacts with protein phosphatase 2A [6] to regulate activity of the mitogen 
activated protein kinase activation pathway and the AP-1 transcription factor activity [7]. T-
Ag and small t-antigen act spontaneously to propel the genesis of prostate epithelial lesions 
and malignant carcinomas and metastases. The TRAMP model is by far the most widely 
used PCA transgenic model for chemoprevention studies because of its simplicity in 
breeding compared to next generations of transgenic models based on deletions, insertions 
or mutations of mouse genes to mimic their changes in human PCA.  
For more than one decade since its inception, the TRAMP model has been believed to 
represent a single lineage of epithelial lesion progression with well-defined kinetics and 
molecular marker alterations. The progression was thought to start from low and high grade 
PIN, to well-differentiated (WD) and moderately-differentiated (MD) adenocarcinoma in the 
dorsolateral prostate lobes (DLP) and finally by stoichastic phenotypic conversion, to poorly 
differentiated adenocarcinomas (PD-Ca) with lymph node and other distant metastases [8]. 
Many subsequent publications interpreted the histology results and molecular 
characterizations using such a paradigm. 
However, several recent studies have suggested that the poorly-differentiated neuro-
endocrine (NE)-like carcinomas (NECa) [9, 10] belonged to a distinct lineage from the 
epithelial lesions, which included low and high grade PIN, WD to MD 
“adenocarcinomas” of the original classification by Dr. Greenburg [8]. Those epithelial 
lesions were recently termed “atypical hyperplasias of T-Ag” (AHT) to distinguish from 
the human prostate cancer pathogenesis because they did not invade adjacent tissues [9]. 
In addition, the incidence of the NECa was found to be profoundly affected by the genetic 
background of the host mice [9]. In the C57BL/6 background, the lifetime incidence of 
NECa was estimated to be about 20% whereas in the FVB background, 87% NECa 
incidence was recorded by as early as 16 weeks of age and reached 100% by 20 weeks of 
age [9]. Furthermore, these NECa mostly arose in the ventral prostate (VP) lobes instead 
of the DLP in both strains [9, 10]. Tissue reconstitution experiments carried out by 
Chiaverotti et al indicated that NECa did not arise from the trans-differentiation of pre-
existing AHT [9]. Tang et al reported that stress induced by anti-cancer treatments 
(castration and/or docetaxol) increased the incidence of NECa in TRAMP mice ((C57BL/6 
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x FVB) F1) [11]. However, the conclusion might be questionable since no mouse in the 
control group had NECa by the time of death, although they all developed 
adenocarcinoma in their prostates. 
These findings significantly challenged the classical notion of single-lineage disease 
progression in the TRAMP DLP [8, 12]. Since the TRAMP model has been increasingly used 
for prostate cancer chemoprevention studies, it is very critical to further characterize the 
lobe-specificity of lesion lineages and NECa incidence in the prostate to consolidate the 
advantages of this model and minimize its limitations for both etiological and 
chemoprevention studies. To experimentally approach this, our group estimated the 
incidence of NECa based on 90 TRAMP mice in the C57BL/6 background spanning the age 
range of 16-50 weeks from several study cohorts [13-15]. We also characterized the 
histological features of different lineages of carcinogenesis in this model using archived 
tissue blocks from those studies [13-15]. In addition, by using state-of-the-art proteomics, we 
sought insights on mechanisms underlying carcinogenesis of different lineages and possible 
targets of chemopreventive reagents [15-17]. Here, we review our results as well as from 
other researchers’ work to provide an objective analysis of the utility of this preclinical 
model for cancer chemoprevention studies. 
3. Histological characteristics of prostate carcinogenesis in TRAMP 
model 
In our studies, the female heterozygous C57BL/TGN TRAMP mice (line PB Tag 8247NG) 
were purchased from The Jackson Laboratory (Bar Harbor, ME), and were cross-bred with 
non-transgenic C57BL/6 males [13-15]. H&E and immuno-histological (IHC) staining were 
routinely performed in our lab and the results are summarized in Table 1 [15]. Figure 1a 
shows the H&E staining of representative morphological features of DLP and VP with 
micro-NECa in TRAMP mice [15]. As can be seen in Figure 1b-1e, the AR-expressing 
glandular prostate epithelial lesions, which are now termed atypical hyperplasias of T-Ag 
(AHT), express nuclear T-Ag, epithelial membrane-staining of E-cadherin and are negative 
for synaptophysin (SYP), which is a neuroendocrine cell marker [15]. Staining of Ki67 
(Figure1f), a proliferative index protein, showed a descending order of NE-Ca >> DLP AHT 
> VP epithelium. In the prostate from wild-type mice, single layer luminal epithelial cells 
were stained positive for nuclear AR, membrane E-cadherin with rare Ki-67 positive 
proliferating cells, while negative for T-Ag and SYP (Figure 2) [13-15]. In contrast, poorly-
differentiated prostate carcinomas (PD) as classified by Greenberg [5] had distinct 
morphological features compared to AHT described above, regardless of the microscopic 
size found within the VP lobe (Figure 1, right panels) or those weighing over many grams 
[15]. Those lesions/tumors expressed strong T-Ag and SYP (except negative in trapped 
glandular epithelial islands), and were negative for AR and E-cadherin (except positive in 
the trapped glandular epithelial islands) [15].  
We analyzed all tumors and prostates in our cohorts with the above panel of biomarkers. 
The incidence of macroscopic tumors (>1 gram) in TRAMP mice of 16-18, 22-24 and 26 
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weeks of age (WOA) were 10%, 20% and 30%, respectively. They were all poorly 
differentiated NECa expressing SYP [13, 15]. In another study, 31 C57BL/6 TRAMP mice in 
the control group (no chemo-preventive agents administrated) were followed up to 50 
WOA. Ten large tumors traceable to the prostate were found (32.3%) and they were all SYP 
positive poorly differentiated NECa [13]. Overall, we observed that there was a trend for 
increasing detection of visible macroscopic NECa in TRAMP mice and the life-time NECa 
incidence rate was 1 out of 3 TRAMP mice from our experiments. This value was slightly 
higher than that reported by Chiaverotti (20%) [9]. The possible reason might be a smaller 
number of and younger C57BL/6 TRAMP mice used in their study [9].  
We attempted to identify the anatomical origin of the NECa. Out of 18 NECa’s in a cohort of 
90 C57BL/6 TRAMP mice of 22 to 24 WOA, 12 were traceable to the VP (66.7%), two tiny 
tumors were traced to DLP (11.1%), whereas 1 large tumor was found in the anterior 
prostate (AP) (5.6%). The other three tumors were not traceable to any lobe location due to 
their overwhelming large sizes. These data were consistent with two recent studies showing 
a preponderance of SYP positive NECa arising from VP in the TRAMP mice of both C57BL/6 
and FVB backgrounds [9, 10]. In contrast, the weight of macroscopic tumor-free VP lobes 
was only slightly increased in TRAMP mice compared to their wild type littermates at 24 
WOA (Table 2 [15]), whereas the DLP lobes underwent significant expansion (more than 
doubled) in the TRAMP mice in one study where these lobes were compared side by side 
[14, 15].  
The Greenberg group had reported the prevalence of seminal vesicles (SV) problems such 
as papillary fibroadenoma in the TRAMP mice with C57BL/6 background shortly after the 
strain was established [12, 18]. Later on, several publications also described the 
histogenesis and pathology of SV neoplasms in the TRAMP mice [19, 20]. In one long-
term survival experiment carried out by our group [13], 54.8% (17 out of 31) TRAMP mice 
in the control group developed tumors in their SV and SV tumor loads became 
significantly increased beyond 30 WOA [13, 15]. Tani et al reported that most of the 
tumors contained phyllode lesions, which were typically composed of single layer 
epithelial linings that were negative for T-Ag, but positive for E-cadherin and AR staining 
and stromal cells that were neoplastic. These stromal cells frequently exhibited mitotic 
figures (BrdU incorporation) and SV40-TAg protein expression in the nuclei and were 
positive for desmin immuno-histological staining [19]. Since they did not observe 
conclusive evidence of malignancy such as invasion or metastasis, they recommended 
diagnosis of the SV tumors as epithelial–stromal tumors. The descriptions matched 
phyllodes-tumors in the C57B/6 TRAMP mice reported by Hsu et al [18]. However, in our 
long term studies, tumors/lesions were found in pelvic lymph nodes, liver, lung or kidney 
of mice without significantly increased prostate size but much enlarged SV in very rare 
cases (<5%), suggesting metastatic lesions from the SV tumors [13, 15]. Tables 1&2 
summarize the expression of biomarkers (by immunohisto staining) and tumor incidence 
in different lineages of carcinogenesis in TRAMP mice [15]. 
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Protein Biomarker Wild type TRAMP TRAMP TRAMP Seminal vesicle 
 
Prostrate AHT* NECa/Metastasis 
Epithelial-stromal 
tumors/Metastasis 
T-Antigen - +++ +++ + 
Androgen Receptor ++ +++ - + 
Synaptophysin - - +++ - 
E-cadherin +++ +++ - -/+ 
Ki-67 (MIB-1) <1% ++ +++ ++ 
*AHT-atypical hyperplasia of T-antigen of glandular epithelia 
 
Table 1. Summary of Immunohistochemical Marker Expression in Prostate lesions and metastases in 
C57BL/6 TRAMP mice [15] 
 
 
 
 
Prostate lobes 
Prostate lobes Dorsolateral Lobe uncertain* Ventral Anterior 
Synaptophysin(+) NE 
carcinoma 
2/18 3/18 12/18 1/18 
#   (%) 11.10% 16.70% 66.70% 5.60% 
Average tumor weight 0.09 4.98 1.65 1.1 
(Weight range), g (0.07, 0.11) (3.44, 4.38, 7.11) (0.02- 4.84) 
TRAMP lobe weight at 24 
weeks, mg 
79.2+3.7 (n =17)** 
 
15.3+1.1 (n=17) ** 
 
Wild type lobe weight at 
24 weeks, mg 
31.7+2.9 (n=8) ** 
 
12.5+1.7 (n=8) ** 
 
t-test p<0.001 p>0.05 
*These 3 big tumors are hard to distinguish the exact originating sites. 
**Presented as mean+SEM. t-test analysis between the TRAMP and wild type mice. 
 
Table 2. Lobe specificity of NECa distribution in 90 TRAMP mice at ≤24 weeks of age (from different 
experiments) [15] 
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Figure 1. Immunohistochemical profiling of key protein markers in dorsal lateral (DLP) and ventral 
prostate (VP) with a microscopic neuroendocrine carcinoma (NECa) from a TRAMP B6 mouse. Serial 
sections were stained for hematoxylin and eosin (HE, a), androgen receptor (AR, b), SV40-T antigen (T-
Ag, c), E-cadherin (d), synaptophysin (e) or Ki67 (Mib1) proliferation-associated protein (f). 
Magnification, 100x. Insets in panels show a higher magnification of staining patterns (400x) [15].  
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Figure 2. IHC staining patterns of wild type and TRAMP prostate for T-antigen (T-ag, nuclear), Ki67 
proliferative antigen (nuclear), E-cadherin (E-Cad, cell membrane), and androgen receptor (AR, nuclear) 
and Synaptophysin (Syp, arrows point to representative positive NE-cells, cytosolic and cell membrane) 
[15]. 
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4. Molecular changes in prostate carcinogenesis in TRAMP model 
Classical methods detecting the steady levels of mRNAs and proteins, as well as “omics” 
approaches such as microarray, antibody array and two-dimension electrophoresis based 
proteomics have been used to study the molecular changes associated with TRAMP 
carcinogenesis using prostate or serum as starting materials. The Greenberg group reported 
increased expression of basic fibroblast growth factor (FGF2) in the prostates (whole 
prostate) of TRAMP mice ([C57BL/6 X FVB] F1) [21]. They found that the expression of the 
25-kDa isoform of FGF2 was 2-fold higher in PIN and WD and MD tumors than in normal 
DLP and VP; the expression of the 22-kDa isoform of FGF2 was not elevated in PIN lesions, 
but was observed to be increased in WD, MD, PD and androgen-independent tumors. 
Interestingly, the 18-kDa isoform of FGF2 was only expressed in the samples representing 
PD and androgen-independent disease. These observations implicated specific changes in 
the FGF axis with the initiation and progression of PCA. The important role of FGF2 in PCA 
progression was further investigated in an in vivo study [22]. In that study, TRAMP mice 
(C57BL/6 background) were crossed with FGF2 knockout (FGF2-/-, SV129 background) mice, 
and tumor progression in TRAMP mice that were either hemi- or homozygous for 
inactivation of the FGF2 allele was compared with wild-type TRAMP mice. They found that 
even inactivation of one FGF2 allele resulted in increased survival, less PD phenotype in 
primary tumors and a decrease in metastasis [22].  Later on, Agarwal’s group reported that 
the chemopreventive effect of dietary silibinin against TRAMP carcinogenesis (C57BL/6 
background) was accompanied with a decreased plasma FGF2 level [23]. The observation 
further suggested FGF2 as a target for chemoprevention of PCA. Similarly, the roles of 
ERKs, EGFR, NF-κB, clusterin, cyclins, insulin-like growth factor-I (IGF-I), DNMTs and 
other molecular pathways in the TRAMP carcinogenesis have also been reported by 
different groups [24-30]. 
Considering extracellular proteolysis as an important biochemical event in the invasion and 
metastasis of PCA, Bok et al studied the expression of matrix metalloproteases (MMP) and 
other related proteins in TRAMP mice (C57BL6/FVB mix) using gelatin zymography [31]. In 
their study, distinct lobes of the prostate (ventral, lateral, dorsal and anterior), seminal 
vesicles, as well as lymph nodes (LN) with metastases were isolated by micro-dissection if 
possible. They found increased expression of mainly pro-MMP 9 and pro-MMP2 in early 
TRAMP tumors, but substantial elevation of activated MMP9 and MMP2 only in late 
TRAMP tumors. In addition, they found a progressive increase in the activities of cysteine, 
serine and certain membrane-bound proteases (cathepsin B, MT-SP1, MT1-MMP) from 
normal to advanced prostate tumors. Interestingly, a gradual decrease in urokinase 
plasminogen activator (uPA) expression with tumor progression was also observed. Overall, 
the study suggested proteases as potential targets for the therapy and secondary prevention 
of PCA. Ruddat et al profiled the proteome of TRAMP ([C57BL/6TRAMPx-FVB] F1) prostate 
by 2-D electrophoresis followed by peptide identification by MALDI-TOF [32]. In their 
study, the WD dorsal prostate (from mice approximately 14 WOA) was compared with 
normal dorsal prostate tissue. The prostates from mice approximately 25 WOA with PD CA 
were not further dissected since it is not practical to differentiate the lobes in an advanced 
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stage. The data revealed that there were few significant changes in the protein abundances 
in the WD dorsal prostates compared to wild-type dorsal prostates, with the exception of 
increases in proliferating cell nuclear antigen (PCNA) and beta tubulin, two proteins 
implicated in cell proliferation, and a more than 2-fold increase in an anti-apoptotic protein 
Hsp60. In contrast, there were substantial changes in protein abundance in the PD tumors 
compared to wild-type dorsal prostates. While some of those changes could be related to the 
disappearance of stromal tissue such as decreased expression of myosin light chain alkali, 
desmin and tropomyosin beta 2, the most notable was the overall decrease in calcium 
homeostasis proteins such as calreticulin and Hsp70 (10-fold decrease) and creatine kinase 
bb (40-fold decrease) in the cancerous tissue. The expression patterns of desmin, Hsp70 and 
calreticulin were further confirmed by Western blot. Although some of their results have 
been cross-validated by us (e.g. down-regulation of calreticulin and tropomyosin beta 2, to 
be discussed later) [16, 17], many of these changes could be due to the differences between 
the cells in the two different carcinogenesis lineages rather than the purported changes due 
to progression of diseases of the Greenberg paradigm. 
Using Affymetrix GeneChip Mouse Genome 430 2.0 micorarrays, Haram et al profiled the 
mRNAs from eight TRAMP (C57BL/6 background, 30±4 WOA)) tumors and DLP or VP of 
nine wild-type mice [33]. Statistical analysis indicated that 3,870 transcripts such as cyclin 
A2, cyclin B1, cyclin B2, cyclin E1, cyclin E2, cyclin F, Forkhead box M1, Aurora Kinase A 
and B were up-regulated in TRAMP tumors and 2,945 transcripts such as cyclin D2 and 
probasin were down-regulated in TRAMP tumors. Real-time RT-PCR confirmed the 
expression of the 11 genes mentioned above. In each real-time PCR experiment, three to four 
normal samples (typically one dorsolateral and three ventral) and four tumors (the same 
four tumor samples in every experiment) were used. Moreover, cross-referencing 
differentially expressed TRAMP genes to public human prostate array datasets revealed 66 
genes with concordant expression in mouse and human PCA. Among the 66 genes, Sox4 
and Tubb2a, which were reported to be up-regulated in primary PCA compared to normal 
prostates, were further validated by real-time RT-PCR. In addition to providing information 
regarding the mechanisms of TRAMP carcinogenesis, the concordance analysis between 
TRAMP and human PCA associated genes also supported the utility of the model. In 
another study, Morgenbesser et al studied the dynamic changes of mRNA profiles in 
TRAMP ([C57BL/6 TRAMP x FVB] F1) mice, especially the genes involved in the acquisition 
of androgen-independent and metastatic tumor growth, using both microarray and SAGE 
approaches [34]. The following cohorts were used in their study: C18 (prostates from wild-
type mice at 18 WOA); C24 (prostates from wild-type mice at 24 WOA); T12 and T18 were 
prostates from TRAMP mice at 12 and 18 WOA representing PIN and MD stages of disease, 
respectively; T24 were PD, androgen-dependent (AD) primary tumors from TRAMP mice at 
24 WOA whereas T(12)24 were PD, androgen-independent (AI) primary tumors from 24-
week-old TRAMP mice that were castrated at 12 WOA. In their paper, differentially 
expressed genes between AD tumors and normal prostates, AI tumors and normal 
prostates, as well as AD and AI tumors were presented. The dynamic changes of ten 
transcripts (e.g. tissue inhibitor of metalloproteinase 4, GATA-binding protein 2, ER-resident 
protein ERdj5, paralemmin, MYC-associated zinc finger protein) over the progress of 
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TRAMP carcinogenesis were further validated by real-time RT-PCR. Their analyses 
uncovered many transcripts that had not previously been implicated in PCA progression, 
especially in the transition from androgen-dependent to androgen-independent status. 
Again, these studies were conducted under the Greenberg paradigm of single lineage 
disease progression. Many of these changes could be due to the differences between the cells 
in the two different carcinogenesis lineages rather than the purported changes due to 
progression of the disease.  
Therefore, it will be prudent to carefully read the descriptions of the tissue samples used in 
the published papers. For example, many older publications prepared lysate from the whole 
prostate whereas very few focused on particular lobes [24, 31, 32]. Recently, researchers 
started to carefully look into the molecular pathways involved in two lineages of 
carcinogenesis (different prostate lobes, mainly DLP and VP) in TRAMP mice after the 
lineage differences of the prostate carcinogenesis had been recognized [9, 13]. For instance, 
Slack-Davis et al studied the requirement for focal adhesion kinase (FAK) signaling in cancer 
progression in TRAMP mice with C57BL/6 background [35]. They found that loss of FAK or 
its inhibition with PF-562271 (small molecular inhibitor for FAK) did not alter the 
progression to AHT. However, continued FAK expression (and activity) is essential for the 
androgen-independent formation of NECa.  
Our group [15] dissected prostate lobes and visible tumors separately in most of our 
experiments in order to assess the lobe-specific biochemical changes. Using these dissected 
lobes/tumors as starting materials, we studied the expression of classical biomarkers by 
immuno-blot. The expression patterns of proliferative cell nuclear antigen (PCNA) (Figure 
3a) confirmed the Ki67 staining patterns by IHC staining described above [15]. Consistent 
with the lack of proliferation of normal prostate epithelium, PCNA was non-detectable in 
the DLP and VP in the wild type mice at 16-18 WOA, whereas significantly higher levels of 
PCNA were detected in the DLP and VP and NECa of TRAMP mice. Since the Ki67 
proliferation index in the VP epithelium appeared to be lower than in TRAMP DLP as 
evidenced by IHC (Figure 1f), the higher level of PCNA in TRAMP VP (Figure 3b) than in 
DLP might be due to the presence of micro NECa foci in the TRAMP VP lobes (NECa has 
much higher Ki67 index, Figure 1f) [15]. We also confirmed the contrasting patterns of AR, 
SYP and E-cadherin expression patterns in the DLP AHT vs. NECa. Although the expression 
of AR and E-cadherin were increased in both DLP and VP in TRAMP mice at 16-18 WOA, 
there were more AR and E-cadherin in VP than in DLP of littermate wild type mice (Figure 
3b) [15]. These patterns are in agreement with that published by the Greenberg group [8, 12] 
and others [9]. In addition, we found that the level of cleaved PARP (endogenous substrate 
for caspase 3) was higher in the NECa than in the DLPs of TRAMP and wild type mice 
(Figure 3a). The STAT3 level in TRAMP DLP was higher than in the wild type DLP and the 
NECa. However, there might be an isoform of STAT3 with higher molecular weight in the 
NECa, indicated by a mobility-retarded band (Figure 3a, arrow) [15]. Our observation was 
consistent with phosphorylative modification and activation of STAT3 in NECa, as reported 
by Aziz et al [36]. The changes of these biomarkers further support molecular differences 
between NECa and DLP AHT.  
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Figure 3. Western blot analyses of protein biomarkers in (A) wild type mouse prostate and in TRAMP 
DLP (DLP) and in NE-Carcinomas (NECa); in (B) DLP and VP of wild type and TRAMP mice at 16-18 
WOA. AR, androgen receptor; PCNA, proliferating cell nuclear antigen; PARP, polyADPribose 
polymerase; STAT3, signal transduction and activator of transcription-3. Arrow marks mobility 
retarded STAT3 that is likely phosphorylated [15]. 
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To provide more information on potential molecular correlates of the differences in DLP and 
VP for epithelial lesions and NE-carcinogenesis, we compared the expression level of 
proteins in respective lobes of wild type vs. TRAMP mice of 18 WOA by the iTRAQ 
proteomic approach, as we recently reported [16, 17]. We employed two-dimensional liquid 
chromatography coupled with tandem mass spectrometry (2D-LC-MS/MS) with iTRAQ 
labeling, which enables the concurrent identification and quantification of proteins through 
peptides generated upon tryptic digestion. The principle and advantages of the platform 
have been described in our previous publications [16, 17, 37]. In total, we identified 1068 
proteins expressed in the DLP and VP of TRAMP mice and wild type mice. Among them, 
483 and 748 proteins were identified at FDRs of 1% and 5% respectively. We found that the 
expression levels of 84 proteins were different between DLP and VP in wild-type mice [17]. 
For example, heat shock protein 5/glucose-regulated protein78 (GRP78), transglutaminase 4 
(TGM4), experimental autoimmune prostatitis antigen 2 (EAPA2), probasin, beta-
tropomyosin, calponin-1, as well as high mobility group box 1 & 2 were preferentially 
expressed in DLP, whereas there were higher levels of prostatic spermine-binding protein 
(SBP), serine peptidase inhibitor Kazal type 3 (SPINK3), polymeric immunoglobulin 
receptor (PIGR), solute carrier family 12 member 2, epidermal growth factor (EGF) and 
clusterin in the VP lobe. The expression pattern of GRP78 and clusterin were validated by 
immuno-blots [17]. The mRNA abundances of prostatic proteins in each lobe of mice or rats 
have been investigated by Fujimoto et al and Berquin et al using PCR and microarray, 
respectively [38-40]. Our results not only agreed with theirs but also extended to more lobe 
specific proteins. Importantly, we found that different sets of proteins were involved in lobe 
specific carcinogenesis in TRAMP mice. The expression levels of 118 proteins were 
significantly altered in DLP and/or VP during TRAMP carcinogenesis. 55 and 36 proteins 
were uniquely changed in DLP or VP respectively and only 27 proteins were found to be 
significantly modulated in both lobes during TRAMP carcinogenesis [17]. The majority (24 
out of 27 proteins) shared the same trend, albeit the extent of change was not exactly the 
same. Shared changes in DLP and VP might indicate possible common molecular events 
associated with carcinogenesis such as elevated proliferation (e.g. up-regulation of 
HMGB1&2 and nuclear proteins such as histone(s)), oxidative stress (e.g. decreased 
antioxidant enzyme PRDX6) and disruption of stroma (e.g. down-regulation of SMMHC 
(myosin-11) and calponin-1) [17]. The three proteins, namely clusterin, polymeric 
immunoglobulin receptor and aldose reductase, which were differentially expressed in DLP 
versus VP, were more likely related to lobe-specific mechanisms of carcinogenesis. 
Interestingly, although some of prostatic proteins had been reported to be regulated by 
androgen signaling [38], EAPA2 and calreticulin were down-regulated in DLP whereas zinc-
alpha-2-glycoprotein was only down-regulated in VP during carcinogenesis. These 
observations suggested that AR signaling could play different roles in carcinogenesis of 
different lobes of TRAMP mice.  
To shed light on the key expression signatures or “master switches” that may not be 
virtually identified due to technical limitation, we analyzed the lists of differentially 
expressed proteins in each lobe by IPA software for pathway connections based on gene 
ontogeny and functionality [17]. Proteins with altered expression in DLP during 
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carcinogenesis were preferentially clustered into Immunological Disease/Cancer/Antigen 
Presentation and Post-Translational Modification/Protein Folding/Cancer networks. 14-3-3 
zeta/delta (YWHAZ, up-regulated only in DLP), NF-κB, epidermal growth factor (EGF, up-
regulated only in DLP), ERK1/2, PKCs were identified as distinct inferred network nodes for 
those networks. On the other hand, proteins with altered expression in VP were mapped to 
Connective Tissue Disorders/Developmental Disorder/Genetic Disorder and Cancer/Cell 
Cycle/Cellular Development pathways with ERK1/2 and FGF2 identified as distinct network 
nodes in the two networks. We further used immunoblot to study the expression pattern of 
FGF2 proteins, which were not identified by LC-MS/MS but unraveled by IPA analysis as 
important proteins in the TRAMP carcinogenesis of the VP lobe. The data indicated that 
different isoforms of FGF2 were expressed in each lobe and FGF2 was only up-regulated in 
the VP lobe of TRAMP mice [17]. To our knowledge, we are the first to systematically 
compare the different protein profile changes between DLP and VP lobes during TRAMP 
carcinogenesis. Our results further support the concept that the C57BL/6 TRAMP mouse 
represents two lineages of prostate carcinogenesis in DLP and VP lobes. Further efforts to 
narrow down possible target proteins and investigation on the functional significance of 
those proteins will not only help understand the mechanisms of TRAMP carcinogenesis, but 
also facilitate the understanding and use of TRAMP model in the field of prostate cancer 
chemoprevention. 
5. Effects of chemopreventive agents on prostate carcinogenesis in 
TRAMP model and possible mechanisms 
Because the breeding strategy of TRAMP mice is straightforward, TRAMP mice have been 
widely used in evaluating potential preventive modalities by many groups in the past 
decade. Besides the effect of androgen deprivation therapy (ADT) on the progression of 
PCA by surgical castration of TRAMP mice [41, 42], the effects of many agents with chemo-
preventive potential including green tea [26, 43],  NSAIDs [44, 45], flutamide [46],  retinoic 
acid [47],  vitamin E analog [48], genistein [24, 49], epigallocatechin-3-gallate (EGCG) [50],  
silibinin [23, 51], dietary restriction [52] and immunotherapy [53, 54], have been studied 
using this model. While most of the publications reported anti-cancer effects of their test 
compounds, El Touny et al showed that feeding TRAMP mice (TRAMP-FVB) with a diet 
containing 0.25% genistein from 12 to 20 WOA induced an aggressive progression of PCA, 
as evidenced by a 16% increase in the number of WD and PD prostates, coinciding with a 
70% incidence of pelvic lymph node metastases as opposed to 0% in the control group [49].  
The recognition of different lineages of carcinogenesis in the TRAMP prostate has 
important implications on the interpretation of chemoprevention data. Due to the distinct 
characteristics of AHT in DLP and NECa in VP, their sensitivity to different chemo-
preventive agents might not be the same. Knowledge of lineage-specific effects of each 
agent will be essential for selecting additional models to confirm the efficacy and to 
ultimately benefit clinical translation studies. In addition, it can provide valuable insights 
into mechanism studies for molecular pathway(s) and targets specific to the particular 
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lineage of carcinogenesis. Using this paradigm, our group evaluated the chemopreventive 
efficacy of next-generation selenium compounds methylseleninic acid (MSeA) and 
methylselenocysteine (MSeC) in TRAMP mice with C57BL/6 background [13]. In a short-
term experiment, TRAMP mice of 8 WOA were given an oral dose of MSeA or MSeC at 3 
mg Se/kg daily and were euthanized at either 18 or 26 WOA. By 18 WOA, the 
genitourinary tract and DLP weights for both treatment groups were lower than for the 
control (p< 0.01). At 26 weeks, 4 of 10 control mice had genitourinary weight >2 g whereas 
only 1 of 10 in each of the treatmente groups did. The efficacy was accompanied by 
delayed lesion progression, increased apoptosis, and decreased proliferation without 
appreciable changes of T-antigen expression in the DLP. In another experiment, giving 
MSeA to TRAMP mice from 10 or 16 WOA increased their survival to 50 weeks of age and 
delayed the death due to SYP-positive NECa, SYP-negative prostate lesions and seminal 
vesicle hypertrophy [13]. Interestingly, although MSeA and MSeC were considered as 
precursors of methylselenol, the proteins they modulated in the DLP of TRAMP mice 
were quite different as indicated by proteomic profiling. The data suggest that MSeA and 
MSeC should be developed as separate agents rather than as equal precursors of 
methylselenol [16]. Very recently, our group also demonstrated that oral administration of 
the alcoholic extract of Angelica gigas (AGN), a traditional Korean herb, had strong 
inhibitory effect on two lineages of carcinogenesis in TRAMP mice, especially the NECa 
[55, 56]. In contrast to the examples of MSeA, MSeC and AGN described above, we also 
published a lack of efficacy of a novel sulindac derivative sulindac sulfide amide (SSA) 
against NECa, whereas it exerted a significant protection against the DLP epithelial 
lesions [14]. Consistent with the fact that NECa originated from VP independently of AR, 
suppressing AR signaling in DLP was one of the important mechanisms underlying the 
chemopreventive effect of SSA, both in vivo and in vitro [14]. Similar to our strategy, 
Harper et al gave TRAMP mice (C57BL/6) water containing 0.06% EGCG starting at 5 
WOA and dissected DLP and VP carefully when mice were euthanized at 12 WOA [50]. 
They found that EGCG significantly reduced the incidence of HG-PIN (Grade 3) from 
100% to 17% in the VP of TRAMP mice but did not have a protective effect in DLP. At 28 
WOA, it was difficult to dissect DLP and VP separately and EGCG did not have any 
inhibitory effect against TRAMP carcinogenesis in general. 
As mentioned above, the life-time NECa incidence has been estimated to be approximately 
30% in TRAMP mice with C57BL/6 background. Rest of the mice will be free of NECa and 
may therefore model the epithelial lineage lesions that are more relevant to the human 
prostate epithelial adeno-carcinogenesis, since the majority of human PCA are 
adenocarcinomas.   
On the other hand, NECa occurs in nearly 100% of the TRAMP mice in the FVB background 
and the DLP undergoes more epithelial lesion growth than does the VP [9, 12]. This might 
have contributed to the assumption that a single lineage of carcinogenesis progressed from 
DLP epithelial lesions to poorly differentiated Ca (i.e., NECa) by the Greenberg group. 
Based on the current information, the C57BL/6 background will be a preferred choice over 
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the FVB background for chemoprevention studies since the former allows a clear separation 
of estimation of the impact of the test agents on both lineages of lesions in the prostate, 
provided that the studies are terminated before SV tumors in the C57BL/6 TRAMP mice 
become a serious complication to survival.  
Since many studies had followed the Greenberg paradigm for interpretation of their 
results, it will be prudent to carefully look into the genetic background of TRAMP mice, 
the manner with which prostate/tumors were collected and the end point(s) chosen to 
evaluate the efficacy. Some of the studies as shown below could be questionable in term 
of the conclusions.   In the study by Adhami et al [43], TRAMP mice (C57BL/6 
background) were given water containing 0.1% green tea polyphenols (GTP) starting at 
ages representing different stage of the disease: 6 WOA (normal prostate), 12 WOA (PIN), 
18 WOA (WD) and 28 WOA (MD). Follow-up monitoring showed that the earlier the 
treatment started, the greater was tumor-free survival extended. The mean genitourinary 
weights showed the same trends. IGF-I and its downstream targets including 
phosphatidylinositol 3-kinase and pAkt were significantly inhibited only when GTP 
treatment was initiated no later than 18WOA. In another study, TRAMP mice (C57BL/6 
background) starting at 4, 12, 20, and 30 WOA were fed with control or 1% silibinin 
supplemented diet for 8 to 15 weeks [51]. In general, silibinin feeding inhibited neoplastic 
progression of the prostate in TRAMP mice at various stages. For the most part, the tumor 
stage at onset time of treatment determined the mechanisms for silibinin’s efficacy. 
Silibinin treatment during the early stages of prostate tumor development in TRAMP 
mice inhibited the progression at PIN stage via anti-proliferation. When the mice were 
burdened with higher stage lesions, silibinin significantly delayed the progression of the 
disease via both anti-proliferative and anti-angiogenesis mechanisms. Anti-angiogenesis, 
along with inhibition of epithelial-mesenchymal transition (EMT) via decreasing the 
expression of MMPs, snail-1, and fibronectin, as well as increasing E-cadherin expression 
levels might also contribute to the anti-metastatic effect of silibinin. Studies aiming to 
define the “stage-specific” efficacy and mechanisms of chemoprevention are very crucial 
for the identification of in vivo targets mediating the chemopreventive effect of 
corresponding agents. In addition, the information will be very important to select the 
right indications for clinical trials. 
6. The concept of cancer stem cells in TRAMP model  
The concept of cancer stem cells (CSC) or tumor-initiating cells assumes that cancers are 
mainly sustained by a small pool of neoplastic cells, which are responsible for cancer 
initiation and/or progression. Although currently no single protein is widely accepted as a 
definitive stem cell marker in the prostate, investigations using in vitro and in vivo models, 
especially tissue recombination strategies, reveal a multifaceted nature of stem cells for 
prostate cancer and highlight the importance of targeting cancer stem cells in the therapy 
and prevention of prostate cancer [57-59]. The role of “cancer stem cells” in TRAMP 
carcinogenesis has received some attention. Chiaverotti et al observed an increased 
frequency of neuroendocrine precursor lesions in TRAMP mice with FVB background as 
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early as 4 WOA [9]. Some of these lesions exhibited properties of bi-potential stem cells as 
evidenced by co-expressing the transcriptional factors Foxa1 and Foxa2, and markers of 
epithelium (E-cadherin) and neuroendocrine (SYP). In their proposed  model of two 
lineages of carcinogenesis [9], a pluripotent stem cell of the normal prostate is 
transformed by SV40 Tag expression and starts to proliferate. Initially these proliferative 
foci maintain a transitional epithelial/NE phenotype co-expressing E-cadherin, SYP, as 
well as Foxa1 and Foxa2. These bipotential cells continue to proliferate, undergo full NE 
differentiation with loss of E-cadherin and then progress to an overt NECa. On the other 
hand, luminal cells of the normal prostate proliferate and form focal areas of hyperplasia 
after transformed by SV40 Tag expression. These foci expand to the entire glandular 
lumen and end up with AHT but do not invade the surrounding stroma and do not 
metastasize. 
Huss et al reported the expression and function of a breast cancer resistance protein 
(BCRP/ABCG2) in putative prostate stem cells and prostate tumor stem cells in several 
models including TRAMP mice (C57BL/6 TRAMP X FVB F1) [60]. BCRP is a member of the 
ATP-binding cassette (ABC) transporter family and expressed consistently by adult stem 
cell populations that possess pluripotentiality and long-term repopulation capability. IHC 
staining indicated that the BCRP+ putative tumor stem cells were localized to foci of AR- 
cells in glands of VP, where the greatest number of NECa would arise after castration. The 
AR- foci that contained the BCRP+ cells were preexisting and not induced by androgen 
deprivation since the frequency of BCRP+ cells was similar in intact (2.0%) and castrated 
(1.8%) TRAMP mice (between 1 and 14 days post-castration). In TRAMP mice, BCRP+/AR- 
cells behaved as label-retaining cells, a stem cell characteristic. The role of BCRP+ putative 
tumor stem cells as the nidus of NECa was further supported by the fact that NECa 
harvested from castrated TRAMP mice contained large focal areas of proliferating, 
BCRP+/AR-/SYP+ cells. BCRP-mediated efflux of androgen might be one of the mechanisms 
for maintenance of the prostate stem cell phenotype since it might be associated with their 
insensitivity to androgen-mediated differentiation and androgen deprivation–induced 
apoptotic cell death. 
ADT was reported to result in a state of androgen independence with more malignant 
behavior in TRAMP mice [41]. Whether certain types of “cancer stem cells” were activated 
during or after castration awaits further investigation. Recently, Tang et al studied the 
effect of surgical castration on the expression of stem cell markers in the prostates of 
TRAMP mice [61]. They castrated TRAMP mice (genetic background not specified) at 12 
WOA and dissected the DLP lobes at two time-points: 10 weeks (Cas-10; n=12) and 20 
weeks (Cas-20; n=9) after castration. They found that stem cell markers Sca-1 (stem cell 
antigen-1), CD133 and c-Kit (CD117) were overexpressed in the luminal cells of the Cas-10 
group, but not in the Cas-20 group. Immuno-blots showed that the expression of bcl-2 and 
GRP78 were significantly higher in the DLP from the Cas-10 compared to that from the 
Cas-20 group. Using anti-Sca-1 antibody conjugated magnetic beads, they estimated the 
abundance of Sca-1 positive cells in the cell suspension prepared by digesting the DLP 
lobes with collagenase/hyaluronidase/DNase I. They found that the abundance of Sca-1 
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cells was more than 3 times higher in the TRAMP Cas-10 group than in wild-type mice at 
12WOA. However, it was dramatically lower in the TRAMP Cas-20 group, which was 
consistent with the IHC data. Although their work described the dynamic expression of 
certain stem cell markers during TRAMP carcinogenesis in DLP, the information is too 
preliminary to draw any conclusion on the effect of castration on “cancer stem cells” in 
TRAMP mice.  
In one recently published paper [15], our group compared different treatment regimens 
with MSeA on TRAMP mice (C57BL/6) to investigate whether MSeA could irreversibly 
inhibit early events in TRAMP carcinogenesis (e.g. activation of “cancer stem cells”). MSeA 
exposure to TRAMP mice (C57BL/6) from 5 to 15 WOA was sufficient to elicit protective 
effects against the two lineages of carcinogenesis to the same extent as continuous MSeA 
exposure from 5 to 23 WOA [15]. Similar findings in a chemically-induced mammary 
carcinogenesis model was reported by Ip et al [62], in which selenium-enriched garlic given 
for 1-month duration right after a single carcinogen exposure was as effective as when it 
was provided throughout the 6-month post-initiation period of the study. Those data 
suggested a possibility that MSeA treatment during the initiation stage of carcinogenesis 
permanently inactivated early critical initiated (“cancer stem”) cells in both lineages. The 
potential mechanisms of inactivation of “cancer stem cells” by MSeA might be apoptosis, 
which is consistent with the pro-apoptotic effect of MSeA and MSeC in TRAMP DLP 
reported previously [13], or another lasting epigenetic modification.  
7. Conclusion  
The paradigm of distinct lineages of carcinogenesis in the TRAMP model and our data with 
MSeA, a sulindac derivative compound and AGN extract shed new light on the utility of 
this preclinical model for chemoprevention studies in spite of much concern regarding of 
the NE nature of the resultant carcinomas and metastasis. Future data collection and 
analyses should incorporate this new knowledge for efficacy assessment and for molecular 
target validations, avoiding ‘‘apple versus orange’’ comparisons. 
Author details 
Jinhui Zhang*, Lei Wang, Yong Zhang and Junxuan Lü* 
Department of Biomedical Sciences, School of Pharmacy, Texas Tech University Health Sciences 
Center, Amarillo, TX, USA 
8. References 
[1] Siegel R, Ward E, Brawley O, Jemal A. (2011) Cancer statistics, 2011: the impact of 
eliminating socioeconomic and racial disparities on premature cancer deaths. CA: a 
cancer journal for clinicians  61(4):212-236. 
                                                                 
* Corresponding Authors 
 
Lobe-Specific Carcinogenesis in the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) Mouse Model 215 
[2] Logothetis CJ, Efstathiou E, Manuguid F, Kirkpatrick P. (2011) Abiraterone acetate. 
Nature Reviews Drug Discovery  10(8):573-574. 
[3] Jeet V, Russell PJ, Khatri A. (2010) Modeling prostate cancer: a perspective on 
transgenic mouse models. Cancer Metastasis Reviews  29(1):123-142. 
[4] Teicher BA. (2006) Tumor models for efficacy determination. Molecular Cancer 
Therapeutics  5(10):2435-2443. 
[5] Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, 
Donjacour AA, Matusik RJ, Rosen JM. (1995) Prostate cancer in a transgenic mouse. 
Proceedings of the National Academy of Sciences of the United States of America  
92(8):3439-3443. 
[6] Pallas DC, Shahrik LK, Martin BL, Jaspers S, Miller TB, Brautigan DL, Roberts TM. 
(1990) Polyoma small and middle T antigens and SV40 small t antigen form stable 
complexes with protein phosphatase 2A. Cell  60(1):167-176. 
[7] Frost JA, Alberts AS, Sontag E, Guan K, Mumby MC, Feramisco JR. (1994) Simian virus 
40 small t antigen cooperates with mitogen-activated kinases to stimulate AP-1 activity. 
Molecular and Cellular Biology  14(9):6244-6252. 
[8] Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison 
LA, Foster BA, Greenberg NM. (2003) Pathobiology of autochthonous prostate cancer in 
a pre-clinical transgenic mouse model. Prostate  55(3):219-237. 
[9] Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, Cunha GR, 
Balmain A. (2008) Dissociation of epithelial and neuroendocrine carcinoma lineages in 
the transgenic adenocarcinoma of mouse prostate model of prostate cancer. The 
American Journal of Pathology  172(1):236-246. 
[10] Huss WJ, Gray DR, Tavakoli K, Marmillion ME, Durham LE, Johnson MA, 
Greenberg NM, Smith GJ. (2007) Origin of androgen-insensitive poorly differentiated 
tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia  
9(11):938-950. 
[11] Tang Y, Wang L, Goloubeva O, Khan MA, Lee D, Hussain A. (2009) The relationship of 
neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice. Prostate  
69(16):1763-1773. 
[12] Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. (1999) Pathologic progression of 
autochthonous prostate cancer in the TRAMP model. Prostate Cancer and Prostatic 
Diseases  2(2):70-75. 
[13] Wang L, Bonorden MJ, Li GX, Lee HJ, Hu H, Zhang Y, Liao JD, Cleary MP, Lu J. (2009) 
Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic 
adenocarcinoma of mouse prostate model with survival benefit. Cancer Prevention 
Research  2(5):484-495. 
[14] Zhang Y, Zhang J, Wang L, Quealy E, Gary BD, Reynolds RC, Piazza GA, Lu J. (2010) A 
novel sulindac derivative lacking cyclooxygenase-inhibitory activities suppresses 
carcinogenesis in the transgenic adenocarcinoma of mouse prostate model. Cancer 
Prevention Research  3(7):885-895. 
 Carcinogenesis 216 
[15] Wang L, Zhang J, Zhang Y, Nkhata K, Quealy E, Liao JD, Cleary MP, Lu J. (2011) Lobe-
specific lineages of carcinogenesis in the transgenic adenocarcinoma of mouse prostate 
and their responses to chemopreventive selenium. Prostate  71(13):1429-1440. 
[16] Zhang J, Wang L, Anderson LB, Witthuhn B, Xu Y, Lu J. (2010) Proteomic profiling of 
potential molecular targets of methyl-selenium compounds in the transgenic 
adenocarcinoma of mouse prostate model. Cancer Prevention Research  3(8):994 
-1006. 
[17] Zhang J, Wang L, Zhang Y, Li L, Higgins L, Lu J. (2011) Lobe-specific proteome changes 
in the dorsal-lateral and ventral prostate of TRAMP mice versus wild-type mice. 
Proteomics  11(12):2542-2549. 
[18] Hsu CX, Ross BD, Chrisp CE, Derrow SZ, Charles LG, Pienta KJ, Greenberg NM, Zeng 
Z, Sanda MG. (1998) Longitudinal cohort analysis of lethal prostate cancer progression 
in transgenic mice. The Journal of Urology  160(4):1500-1505. 
[19] Tani Y, Suttie A, Flake GP, Nyska A, Maronpot RR. (2005) Epithelial-stromal tumor of 
the seminal vesicles in the transgenic adenocarcinoma mouse prostate model. 
Veterinary Pathology  42(3):306-314. 
[20] Yeh IT, Reddick RL, Kumar AP. (2009) Malignancy arising in seminal vesicles in the 
transgenic adenocarcinoma of mouse prostate (TRAMP) model. Prostate  69(7):755-
760. 
[21] Huss WJ, Barrios RJ, Foster BA, Greenberg NM. (2003) Differential expression of 
specific FGF ligand and receptor isoforms during angiogenesis associated with prostate 
cancer progression. Prostate  54(1):8-16. 
[22] Polnaszek N, Kwabi-Addo B, Peterson LE, Ozen M, Greenberg NM, Ortega S, 
Basilico C, Ittmann M. (2003) Fibroblast growth factor 2 promotes tumor progression 
in an autochthonous mouse model of prostate cancer. Cancer Research  63(18):5754-
5760. 
[23] Singh RP, Raina K, Sharma G, Agarwal R. (2008) Silibinin inhibits established prostate 
tumor growth, progression, invasion, and metastasis and suppresses tumor 
angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of 
the mouse prostate model mice. Clinical Cancer Research : an official journal of the 
American Association for Cancer Research  14(23):7773-7780. 
[24] Wang J, Eltoum IE, Lamartiniere CA. (2004) Genistein alters growth factor signaling in 
transgenic prostate model (TRAMP). Molecular and Cellular Endocrinology  219(1-
2):171-180. 
[25] Shukla S, Maclennan GT, Marengo SR, Resnick MI, Gupta S. (2005) Constitutive 
activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in 
autochthonous transgenic mouse model. Prostate  64(3):224-239. 
[26] Caporali A, Davalli P, Astancolle S, D'Arca D, Brausi M, Bettuzzi S, Corti A. (2004) The 
chemopreventive action of catechins in the TRAMP mouse model of prostate 
carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis  
25(11):2217-2224. 
 
Lobe-Specific Carcinogenesis in the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) Mouse Model 217 
[27] Maddison LA, Huss WJ, Barrios RM, Greenberg NM. (2004) Differential expression of 
cell cycle regulatory molecules and evidence for a "cyclin switch" during progression of 
prostate cancer. Prostate  58(4):335-344. 
[28] Morey Kinney SR, Smiraglia DJ, James SR, Moser MT, Foster BA, Karpf AR. (2008) 
Stage-specific alterations of DNA methyltransferase expression, DNA 
hypermethylation, and DNA hypomethylation during prostate cancer progression in 
the transgenic adenocarcinoma of mouse prostate model. Molecular Cancer Research 
6(8):1365-1374. 
[29] Kinney SR, Moser MT, Pascual M, Greally JM, Foster BA, Karpf AR. (2010) Opposing 
roles of Dnmt1 in early- and late-stage murine prostate cancer. Molecular and Cellular 
Biology 30(17):4159-4174. 
[30] Majeed N, Blouin MJ, Kaplan-Lefko PJ, Barry-Shaw J, Greenberg NM, Gaudreau P, 
Bismar TA, Pollak M. (2005) A germ line mutation that delays prostate cancer 
progression and prolongs survival in a murine prostate cancer model. Oncogene  
24(29):4736-4740. 
[31] Bok RA, Hansell EJ, Nguyen TP, Greenberg NM, McKerrow JH, Shuman MA. (2003) 
Patterns of protease production during prostate cancer progression: proteomic 
evidence for cascades in a transgenic model. Prostate Cancer and Prostatic diseases  
6(4):272-280. 
[32] Ruddat VC, Whitman S, Klein RD, Fischer SM, Holman TR. (2005) Evidence for 
downregulation of calcium signaling proteins in advanced mouse adenocarcinoma. 
Prostate  64(2):128-138. 
[33] Haram KM, Peltier HJ, Lu B, Bhasin M, Otu HH, Choy B, Regan M, Libermann TA, 
Latham GJ, Sanda MG et al. (2008) Gene expression profile of mouse prostate tumors 
reveals dysregulations in major biological processes and identifies potential murine 
targets for preclinical development of human prostate cancer therapy. Prostate  
68(14):1517-1530. 
[34] Morgenbesser SD, McLaren RP, Richards B, Zhang M, Akmaev VR, Winter SF, Mineva 
ND, Kaplan-Lefko PJ, Foster BA, Cook BP et al. (2007) Identification of genes potentially 
involved in the acquisition of androgen-independent and metastatic tumor growth in 
an autochthonous genetically engineered mouse prostate cancer model. Prostate  
67(1):83-106. 
[35] Slack-Davis JK, Hershey ED, Theodorescu D, Frierson HF, Parsons JT. (2009) 
Differential requirement for focal adhesion kinase signaling in cancer progression in the 
transgenic adenocarcinoma of mouse prostate model. Molecular Cancer Therapeutics  
8(8):2470-2477. 
[36] Aziz MH, Manoharan HT, Church DR, Dreckschmidt NE, Zhong W, Oberley TD, 
Wilding G, Verma AK. (2007) Protein kinase Cepsilon interacts with signal 
transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and 
regulates its constitutive activation in prostate cancer. Cancer Research  67(18):8828-
8838. 
[37] Zhang J, Nkhata K, Shaik AA, Wang L, Li L, Zhang Y, Higgins LA, Kim KH, Liao JD, 
Xing C et al. (2011) Mouse prostate proteome changes induced by oral 
 Carcinogenesis 218 
pentagalloylglucose treatment suggest targets for cancer chemoprevention. Current 
Cancer Drug Targets  11(7):787-798. 
[38] Fujimoto N, Akimoto Y, Suzuki T, Kitamura S, Ohta S. (2006) Identification of prostatic-
secreted proteins in mice by mass spectrometric analysis and evaluation of lobe-specific 
and androgen-dependent mRNA expression. The Journal of Endocrinology  190(3):793-
803. 
[39] Fujimoto N, Suzuki T, Ohta S, Kitamura S. (2009) Identification of rat prostatic secreted 
proteins using mass spectrometric analysis and androgen-dependent mRNA 
expression. Journal of Andrology  30(6):669-678. 
[40] Berquin IM, Min Y, Wu R, Wu H, Chen YQ. (2005) Expression signature of the mouse 
prostate. The Journal of Biological Chemistry  280(43):36442-36451. 
[41] Tang Y, Wang L, Goloubeva O, Khan MA, Zhang B, Hussain A. (2008) Divergent effects 
of castration on prostate cancer in TRAMP mice: possible implications for therapy. 
Clinical cancer research : an official journal of the American Association for Cancer 
Research  14(10):2936-2943. 
[42] Zhang ZX, Xu QQ, Huang XB, Zhu JC, Wang XF. (2009) Early and delayed castrations 
confer a similar survival advantage in TRAMP mice. Asian Journal of Andrology  
11(3):291-297. 
[43] Adhami VM, Siddiqui IA, Sarfaraz S, Khwaja SI, Hafeez BB, Ahmad N, Mukhtar H. 
(2009) Effective prostate cancer chemopreventive intervention with green tea 
polyphenols in the TRAMP model depends on the stage of the disease. Clinical Cancer 
Research : an official journal of the American Association for Cancer Research  
15(6):1947-1953. 
[44] Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P, 
Mukhtar H. (2004) Suppression of prostate carcinogenesis by dietary supplementation 
of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer 
Research  64(9):3334-3343. 
[45] Narayanan BA, Narayanan NK, Pittman B, Reddy BS. (2004) Regression of mouse 
prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the 
transgenic adenocarcinoma mouse prostate model. Clinical Cancer Research : an official 
journal of the American Association for Cancer Research  10(22):7727-7737. 
[46] Raghow S, Kuliyev E, Steakley M, Greenberg N, Steiner MS. (2000) Efficacious 
chemoprevention of primary prostate cancer by flutamide in an autochthonous 
transgenic model. Cancer Research  60(15):4093-4097. 
[47] Huss WJ, Lai L, Barrios RJ, Hirschi KK, Greenberg NM. (2004) Retinoic acid slows 
progression and promotes apoptosis of spontaneous prostate cancer. Prostate  61(2):142-
152. 
[48] Yin Y, Ni J, Chen M, DiMaggio MA, Guo Y, Yeh S. (2007) The therapeutic and 
preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of 
insulin-like growth factor binding protein-3. Clinical Cancer Research : an official 
journal of the American Association for Cancer Research  13(7):2271-2280. 
 
Lobe-Specific Carcinogenesis in the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) Mouse Model 219 
[49] El Touny LH, Banerjee PP. (2009) Identification of a biphasic role for genistein in the 
regulation of prostate cancer growth and metastasis. Cancer Research  69(8):3695-
3703. 
[50] Harper CE, Patel BB, Wang J, Eltoum IA, Lamartiniere CA. (2007) Epigallocatechin-3-
Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: 
mechanisms of action. Prostate  67(14):1576-1589. 
[51] Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R. (2008) Stage-
specific inhibitory effects and associated mechanisms of silibinin on tumor progression 
and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer 
Research  68(16):6822-6830. 
[52] Suttie AW, Dinse GE, Nyska A, Moser GJ, Goldsworthy TL, Maronpot RR. (2005) An 
investigation of the effects of late-onset dietary restriction on prostate cancer 
development in the TRAMP mouse. Toxicologic Pathology  33(3):386-397. 
[53] Gray A, de la Luz Garcia-Hernandez M, van West M, Kanodia S, Hubby B, Kast 
WM. (2009) Prostate cancer immunotherapy yields superior long-term survival in 
TRAMP mice when administered at an early stage of carcinogenesis prior to the 
establishment of tumor-associated immunosuppression at later stages. Vaccine  27 
Suppl 6:G52-59. 
[54] Liu Z, Eltoum IE, Guo B, Beck BH, Cloud GA, Lopez RD. (2008) Protective 
immunosurveillance and therapeutic antitumor activity of gammadelta T cells 
demonstrated in a mouse model of prostate cancer. Journal of Immunology  
180(9):6044-6053. 
[55] Lei Wang,  Yong Zhang, Jinhui Zhang, Katai Nkata, Emily Quealy, Li Li, Hyo-Jeong 
Lee, Soo-Jin Jeong, Joshua Liao, Cheng Jiang, Sung-Hoon Kim, and Junxuan Lu. (2011) 
Korean Angelica gigas Nakai (AGN) and Oriental herbal cocktail ka-mi-kae-kyuk-tang 
(KMKKT) inhibit prostate carcinogenesis in TRAMP model. Cancer Research  71(8 
(Suppl)):Abstract nr 5581. 
[56] Jinhui Zhang,  Li Li, Yong Zhang, Lei Wang, Cheng Jiang, Sung-Hoon kim, and 
Junxuan Lu. (2012) Proteomic and transcriptomic profiling of effects of Angelica gigas 
ethanol extract on prostate neuroendocrine carcinomas of TRAMP mice. Cancer 
Research  72(8 (Suppl)):Abstract nr 2587. 
[57] Cheng L, Ramesh AV, Flesken-Nikitin A, Choi J, Nikitin AY. (2010) Mouse models for 
cancer stem cell research. Toxicologic Pathology  38(1):62-71. 
[58] Taylor RA, Toivanen R, Risbridger GP. (2010) Stem cells in prostate cancer: treating the 
root of the problem. Endocrine-related cancer  17(4):R273-285. 
[59] Miki J. (2010) Investigations of prostate epithelial stem cells and prostate cancer stem 
cells. International Journal of Urology : official journal of the Japanese Urological 
Association  17(2):139-147. 
[60] Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ. (2005) Breast cancer resistance 
protein-mediated efflux of androgen in putative benign and malignant prostate stem 
cells. Cancer Research  65(15):6640-6650. 
 Carcinogenesis 220 
[61] Tang Y, Hamburger AW, Wang L, Khan MA, Hussain A. (2009) Androgen deprivation 
and stem cell markers in prostate cancers. International Journal of Clinical and 
Experimental Pathology  3(2):128-138. 
[62] Ip C, Lisk DJ, Thompson HJ. (1996) Selenium-enriched garlic inhibits the early stage but 
not the late stage of mammary carcinogenesis. Carcinogenesis  17(9):1979-1982. 
